Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | PRKACG | P22612 | 1/20 | 0.39 |
| ▸ | PRKACB | P22694 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220869 | 0.92 | PRKACA (0.41) | PRKACAPRKACGPRKACBKDM1ANR1H2 | |
| SCHEMBL9821524 | 0.83 | PRKACA (0.44) | PRKACAPRKACGPRKACBKDM1AGPR119 | |
| SCHEMBL30027630 | 0.79 | KDM1A (0.46) | PRKACAPRKACGPRKACBKDM1AGPR119 | |
| SCHEMBL21209965 | 0.79 | KDM1A (0.46) | PRKACAPRKACGPRKACBKDM1AGPR119 | |
| SCHEMBL5560252 | 0.79 | KDM1A (0.44) | PRKACAPRKACGPRKACBKDM1AGPR119 | |
| SCHEMBL3956182 | 0.78 | KDM1A (0.43) | PRKACAPRKACGPRKACBKDM1AGPR119 | |
| SCHEMBL30681400 | 0.78 | KDM1A (0.46) | PRKACAPRKACGPRKACBKDM1AGPR119 | |
| SCHEMBL20506532 | 0.78 | KDM1A (0.43) | PRKACAPRKACGPRKACBKDM1AGPR119 | |
| SCHEMBL3959703 | 0.78 | KDM1A (0.43) | PRKACAPRKACGPRKACBKDM1AGPR119 | |
| SCHEMBL3956185 | 0.78 | KDM1A (0.43) | PRKACAPRKACGPRKACBKDM1AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552044-B2 | Dopamine receptors | H. LUNDBECK A/S (DK) | 2003-04-22 | — | — | US | disclosed |
| EP-0946542-B1 | INDANE OR DIHYDROINDOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2002-10-09 | — | — | EP | disclosed |
| US-6352988-B2 | HIGH AFFINITY FOR D4 RECEPTORS; TREATMENT OF SCHIZOPHRENIA, OTHER PSYCHOSES, ANXIETY DISORDERS, DEPRESSION, ALCOHOL ABUSE, IMPULSE CONTROL DISORDERS, AGGRESSION | H. LUNDBECK A/S (DK) | 2002-03-05 | — | — | US | disclosed |
| US-20010021777-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-09-13 | — | — | US | disclosed |
| US-20010020095-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-09-06 | — | — | US | disclosed |
| US-6262087-B1 | HAVE HIGH AFFINITY FOR D4 RECEPTORS; USEFUL IN THE TREATMENT OF CERTAIN PSYCHIATRIC AND NEUROLOGIC DISORDERS, INCLUDING PSYCHOSIS, DEPRESSION AND ANXIETY. | H. LUNDBECK A/S (DK) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020095-A1 | Indane or dihydroindole derivatives | HTR4, GPR4, GPR174 | PRKACA 4345/4885PRKACG 4682/4885PRKACB 4676/4885 |
| US-20010021777-A1 | Indane or dihydroindole derivatives | HTR4, GPR4, GPR174 | PRKACA 4345/4885PRKACG 4682/4885PRKACB 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.